GGrantIndex
← Leaderboards

Fred Hutchinson Cancer Research Center

Seattle, WA

Compare ↔
$5,551,458,056
Total funding
2,060
Grants

Funding over time

peak $804.9M · FY2005–22
$1B$750M$500M$250M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$5,481,499,031 · 1965
DOD$65,430,488 · 73
NSF$7,885,183 · 15
CDC$1,695,676 · 3
FDA$436,229 · 1
USDA$180,052 · 1
AHRQ$40,782 · 2
DOE$-54,035 · 1

By mechanism

UM1$1,627,498,434 · 11
R01$1,377,820,772 · 594
U01$926,106,028 · 83
P01$261,766,675 · 216
N01$254,585,919 · 30
P30$142,421,428 · 175

Investigators at Fred Hutchinson Cancer Research Center

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Silvia Balbo$4,759,5724 gr2Michael Chiao-An Wu$4,278,1873 gr3Evan Newell$3,042,3801 gr4Veena Shankaran$3,029,9541 gr5Nicolas John Lehrbach$2,304,1581 gr6Emily M Hatch$2,200,0001 gr7Aakanksha Singhvi$2,178,4581 gr8Molly Ohainle$2,161,2501 gr

All-Time

Most funded here, all years

1Robert Neil Eisenman$32,865,0638 gr2Jonathan B Bricker$28,496,50310 gr3Mark T Groudine$27,181,0875 gr4Gerald R Smith$25,921,2855 gr5Steven M Hahn$24,844,7954 gr6Philippe M Soriano$22,387,7054 gr7David Neal Fredricks$22,150,52014 gr8Johanna W Lampe$22,137,14420 gr

Largest grants

HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals$393,953,893
UM1 · FY2020 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$61,429,109
UM1 · FY2021 · AI
LOC: HIV Vaccine Trials Network$55,377,361
UM1 · FY2018 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$52,490,835
U01 · FY2006 · AI
LOC: HIV Vaccine Trials Network$50,375,222
UM1 · FY2017 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$43,124,622
UM1 · FY2021 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$41,690,531
U01 · FY2007 · AI
LOC: HIV Vaccine Trials Network$40,823,093
UM1 · FY2020 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$40,320,056
UM1 · FY2021 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$37,287,824
UM1 · FY2011 · AI
LOC: HIV Vaccine Trials Network$36,427,285
UM1 · FY2014 · AI
LOC: HIV Vaccine Trials Network$36,148,992
UM1 · FY2019 · AI
LC: HIV Vaccine Trials Network$35,486,174
UM1 · FY2018 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$34,168,787
U01 · FY2009 · AI
HIV Vaccine Trials Network Laboratory Center$33,072,609
UM1 · FY2021 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$32,353,045
UM1 · FY2012 · AI
LOC: HIV Vaccine Trials Network$30,221,723
UM1 · FY2016 · AI
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC$29,952,323
UM1 · FY2020 · AI
Leadership Group for a Global HIV Vaccine Clinical Trials Network$26,907,846
U01 · FY2008 · AI
SDMC: HIV Vaccine Trials Network$26,398,527
UM1 · FY2021 · AI